John is currently the Scientific Affairs Lead for Genomics & Oncology at Roche Molecular Diagnostics, where he previously served as the Clinical Research Lead for Blood Screening. Prior to Roche, John was the Director of Medical & Clinical Affairs and Head of R&D at RedPath Integrated Pathology. Before that, he managed the discovery and early development teams for the identification of novel diagnostic biomarkers in oncology and diabetes at Veridex, a Johnson & Johnson company. In this role, he managed numerous non-registrational, clinical collaborations and lead registrational studies for submission to the FDA. Prior to Veridex, John was the director of emerging markets & molecular diagnostics research at Affymetrix, where he was the lead scientist for the FDA submission of the GCS3000Dx microarray platform that was used in conjunction with the Amplichip P450 array.
John earned his Ph.D. from the State University of New York in Brooklyn with a focus in molecular genomics where he studied b-globin transcriptional regulation. Over the last 20 years, he has published peer-reviewed papers and obtained patents in oncology, diabetes and molecular diagnostics.